<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03259633</url>
  </required_header>
  <id_info>
    <org_study_id>D1346R00002</org_study_id>
    <secondary_id>D1346R00002</secondary_id>
    <nct_id>NCT03259633</nct_id>
  </id_info>
  <brief_title>An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1</brief_title>
  <official_title>An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1 With Inoperable, Progressive/Symptomatic Plexiform Neurofibromas (PN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This will be an open-label, single-arm, multicenter intermediate access protocol which&#xD;
      provides treatment access to selumetinib for eligible patients with neurofibromatosis type 1&#xD;
      (NF1) who have inoperable, progressive/symptomatic plexiform neurofibromas (PN) without any&#xD;
      alternative therapeutic options. All patients will continue to receive drug while they are&#xD;
      deriving clinical benefit.&#xD;
&#xD;
      Approximately 100 patients in the US will be treated as part of this protocol&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients must have received a clinical diagnosis of NF1 and have inoperable,&#xD;
      progressive/symptomatic PN, where inoperable is defined as PN that cannot be surgically&#xD;
      completely removed without risk of substantial morbidity.&#xD;
&#xD;
      The population are patients with NF1 who have inoperable, progressive/symptomatic PN aged ≥&#xD;
      2years with onset of disease before they were 18 years and who have demonstrated an ability&#xD;
      to swallow whole capsules, who have no further treatment options and are not eligible for&#xD;
      clinical trials.&#xD;
&#xD;
      There is no maximum duration for selumetinib treatment. Patients may continue to receive&#xD;
      selumetinib as long as they continue to show clinical benefit, as judged by the treating&#xD;
      physician, and in the absence of unacceptable toxicity.&#xD;
&#xD;
      Once patients have been discontinued from treatment, other available treatment options will&#xD;
      be at the discretion of the physician&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>NF type1 With Inoperable Plexiform Neurofibromas</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selumetinib</intervention_name>
    <description>open-label, single-arm, multicenter intermediate access protocol</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of neurofibromatosis type 1 (NF1) and have inoperable,&#xD;
             progressive/symptomatic plexiform neurofibromas (PN)&#xD;
&#xD;
          2. Presence of inoperable PN , defined as a PN that cannot be surgically completely&#xD;
             removed without risk for substantial morbidity&#xD;
&#xD;
          3. Patients aged ≥2 with onset of disease before they were 18 years and a BSA ≥ 0.55 m2&#xD;
             who are able to swallow whole capsules. (approx. length 15.4 mm, diameter 5.4 mm). A&#xD;
             swallow test must be performed before requesting drug&#xD;
&#xD;
          4. Normal cardiac function defined as normal ejection fraction (ECHO, MUGA or cardiac&#xD;
             MRI) as per institutional normal and absence of prior heart disease&#xD;
&#xD;
          5. Adequate blood pressure as defined in line with local practice.&#xD;
&#xD;
          6. The patient has exhausted all available approved therapies as appropriate for NF1 with&#xD;
             inoperable progressive/symptomatic PN&#xD;
&#xD;
          7. Provision of a signed informed consent prior to any protocol specific procedures.&#xD;
             Patients already receiving selumetinib through single patient access who enroll in&#xD;
             this protocol must be reconsented and sign the consent form for this intermediate&#xD;
             access protocol.&#xD;
&#xD;
          8. For female patients of childbearing potential, have evidence of a post-menopausal&#xD;
             status, or a negative urinary or serum pregnancy test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unresolved chronic toxicity ≥ CTCAE Grade 2 from previous therapy&#xD;
&#xD;
          2. Patients eligible for any ongoing clinical trials with selumetinib in the indication&#xD;
             in question&#xD;
&#xD;
          3. Ophthalmological conditions: Current or past history of retinal pigment epithelial&#xD;
             detachment (RPED)/central serous retinopathy (CSR) or retinal vein occlusion&#xD;
             Intraocular pressure (IOP) should not be &gt; 21 mmHg for adults or outside the range of&#xD;
             normal for children or uncontrolled glaucoma (irrespective of IOP)&#xD;
&#xD;
          4. Male or female patients of reproductive potential and, as judged by the investigator,&#xD;
             are not employing an effective method of birth control.&#xD;
&#xD;
          5. Female patients who are breast-feeding.&#xD;
&#xD;
          6. Have evidence of any other significant clinical disorder or laboratory finding that,&#xD;
             as judged by the treating physician, makes it undesirable for the patient to&#xD;
             participate in the study.&#xD;
&#xD;
          7. Have any evidence of a severe or uncontrolled systemic disease (e.g. unstable or&#xD;
             uncompensated respiratory, cardiac, hepatic, or renal disease, active infection&#xD;
             (including hepatitis B, hepatitis C, HIV), active bleeding diatheses or renal&#xD;
             transplant&#xD;
&#xD;
          8. Have refractory nausea and vomiting, chronic gastrointestinal diseases (e.g.,&#xD;
             inflammatory bowel disease), or significant bowel resection that would adversely&#xD;
             affect the absorption / bioavailability of the orally administered study medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miriam Bornhorst, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>12345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 21, 2017</study_first_submitted>
  <study_first_submitted_qc>August 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2017</study_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neurofibromatosis type1,</keyword>
  <keyword>Plexiform Neurofibromas</keyword>
  <keyword>inoperable, progressive/symptomatic plexiform neurofibromas (PN) without any alternative therapeutic options</keyword>
  <keyword>mutation in the NF1 gene</keyword>
  <keyword>Selumetinib</keyword>
  <keyword>Early Access</keyword>
  <keyword>Intermediate Access Protocol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurofibromatosis 1</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
    <mesh_term>Neurofibroma, Plexiform</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03259633
org study id: D1346R00002
secondary id: D1346R00002
nct id: NCT03259633
lead sponsor: 
This will be an open-label, single-arm, multicenter intermediate access protocol which
      provides treatment access to selumetinib for eligible patients with neurofibromatosis type 1
      (NF1) who have inoperable, progressive/symptomatic plexiform neurofibromas (PN) without any
      alternative therapeutic options. All patients will continue to receive drug while they are
      deriving clinical benefit.

      Approximately 100 patients in the US will be treated as part of this protocol
Patients must have received a clinical diagnosis of NF1 and have inoperable,
      progressive/symptomatic PN, where inoperable is defined as PN that cannot be surgically
      completely removed without risk of substantial morbidity.

      The population are patients with NF1 who have inoperable, progressive/symptomatic PN aged ≥
      2years with onset of disease before they were 18 years and who have demonstrated an ability
      to swallow whole capsules, who have no further treatment options and are not eligible for
      clinical trials.

      There is no maximum duration for selumetinib treatment. Patients may continue to receive
      selumetinib as long as they continue to show clinical benefit, as judged by the treating
      physician, and in the absence of unacceptable toxicity.

      Once patients have been discontinued from treatment, other available treatment options will
      be at the discretion of the physician
expanded access type intermediate: Yes
intervention type: Drug
intervention name: Selumetinib
description: open-label, single-arm, multicenter intermediate access protocol
criteria: 
gender: All
minimum age: 2 Years
maximum age: 130 Years
healthy volunteers: No
last name: Miriam Bornhorst, MD
role: Principal Investigator
affiliation: Investigator
facility: 
country: United States
responsible party type: Sponsor
mesh term: Neurofibromatoses
mesh term: Neurofibromatosis 1
mesh term: Neurofibroma
mesh term: Neurofibroma, Plexiform